Clin2
NCT05231798Possibly a fitRecruiting

PET and brain scans in adults with Down syndrome

Down SyndromeDown Syndrome, Partial Trisomy 21Alzheimer Disease

Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.

This study looks at how well a brain chemical system works in adults with Down syndrome as they age, including how it relates to Alzheimer’s-type brain changes and thinking skills. It uses brain scans and memory/thinking tests to see whether these measures can help track risk or changes over time.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
18 years to 55 years
Study type
Interventional

Who can take part

  • You have Down syndrome (including mosaic or partial trisomy 21)
  • You’re between 18 and 55 years old, and you do not currently have dementia
  • You can take part for the full study, including brain scans and thinking tests
  • Your vision and hearing are good enough to complete the thinking tests
  • If you take brain/cancer/nerve medicines that affect the brain, your dose must be stable for about 4 weeks (or the team reviews timing)
  • A reliable study partner (caregiver or family member) can share your history and symptoms

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04165109Recruiting
Down syndrome study to test memory and thinking changes

This study enrolls adults with Down syndrome to better understand how thinking and memory develop and change over time. It may help by building a “trial-ready” group and by measuring thinking in a careful, consistent way.

Phoenix, Arizona
NCT05374278Recruiting· Phase 1/Phase 2
PET scan test for a dementia brain tracer

This early-phase study tests a new PET scan tracer that targets a brain chemical transport system involved in dementia. It aims to see if the tracer can safely and clearly show brain changes, which could help future dementia diagnosis or tracking.

San Francisco, California
NCT06911944Not yet recruiting· Phase 4
Donanemab for Alzheimer's in Down syndrome

This trial tests if an investigational drug called donanemab can lower amyloid plaques in the brain to slow Alzheimer's disease in adults with Down syndrome. Participants must be 35–50, have elevated brain amyloid, and not have dementia yet.

NCT05582200Recruiting
PET brain scan to study inflammation cells in Alzheimer’s

This study uses a special PET brain scan to look at two types of brain immune cells in people with Alzheimer’s. It may help researchers better understand Alzheimer’s and how these cells change over time.

Houston, Texas
NCT02414178Enrolling by invitation
Tau PET brain scan for inherited Alzheimer’s disease

This study uses a special brain scan to measure “tau” buildup in people with an inherited form of Alzheimer’s. It may help researchers better understand disease changes and evaluate whether the scan can track them over time.

St Louis, Missouri
NCT06445582Not yet recruiting
SV2A-PET scans for early memory problem diagnosis

This study uses special PET scans (SV2A-PET/CT and PET/MRI) to see if they can help diagnose early memory changes, including Alzheimer's disease and mild cognitive impairment (MCI). If you have early Alzheimer's or MCI, this could help find better ways to detect and track the disease.

Hear when a new Down Syndrome trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.